search
Back to results

Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon (RAY-GENE)

Primary Purpose

Primary Raynaud's Phenomenon (PR), Genetic Mutations Causing PR, Study of Patients and Their Relatives (With or Without Primary PR)

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Demonstration of genetic mutations causing Raynaud's phenomenon
Sponsored by
Nantes University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Primary Raynaud's Phenomenon (PR) focused on measuring Raynaud's phenomenon, Vasospasm, Genetics

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria:

  • Major Subject (age ≥ 18 years)
  • Index case with all the diagnostic criteria for primary Raynaud phenomenon, according to current recommendations OR Related index case (relatives' patients) with or without a primary Raynaud phenomenon.
  • Written consent to participate in the study
  • Written consent to participate in the collection of biological samples

Exclusion criteria:

  • Subjects who have expressed their inability or refusal to sign an informed consent,
  • Index case with a secondary Raynaud phenomenon (suspected by clinical examination and confirmed by capillaroscopy and laboratory tests: antinuclear antibody, abnormalities of capillaroscopy mégacapillaire dystrophy or other major deviation).

(Criterion not applicable to related parties, i.e. family members of Index cases)

- Pregnant Woman.

Sites / Locations

  • CHU Angers - Service d'Explorations vasculaires
  • CHRU HOPITAL CAVALE BLANCHE - Service de Médecine vasculaire
  • CHD La Roche sur Yon - Service Angéiologie
  • CHU de NANTES - Service de Médecine Interne
  • C.H.R. HOPITAL SUD - Service de Médecine interne
  • Ch Saint Nazaire

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Patient with Raynaud's phenomenon

Arm Description

Outcomes

Primary Outcome Measures

To identify number of genes involved in vasospasm of primary Raynaud's phenomenon (RP) and determine the genetic cause of primary RP
Patients with primary Raynaud's phenomenon and their relatives will be recruited to establish familial forms of Raynaud's phenomenon. This will allow perform genetic analysis using new approaches to genetic broadband (exome sequencing analysis + linkage analysis). This approach will allow specify which chromosomal regions are shared only by affected individuals, and identify new candidate genes

Secondary Outcome Measures

To determine number of phenotypes associated to genotype of primary Raynaud's phenomenon
Based on the identified genes in different families, a descriptive analysis will allow associate them with different RP phenotypes (isolated RP or RP associated with migraines, angina or hypertension) and risk factors.

Full Information

First Posted
July 15, 2014
Last Updated
June 22, 2020
Sponsor
Nantes University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02202291
Brief Title
Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon
Acronym
RAY-GENE
Official Title
Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
October 13, 2014 (Actual)
Primary Completion Date
June 10, 2020 (Actual)
Study Completion Date
June 10, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nantes University Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Vasospasm is a transient contraction causing a decrease in caliber of a vessel and thus a decrease in vascularization in a vascular territory leading to suffering of tissue in the sector concerned. Vasospasm-related diseases have different clinical presentations such as migraine, spastic angina, hypertension related to vasospasm or primary Raynaud's phenomenon (RP). These diseases have few therapeutic methods due to poorly understood pathophysiology. For migraine and angina, the vascular exploration is problematic unlike for primary Raynaud's phenomenon (RP). Primary Raynaud's phenomenon (RP) is a common peripheral vascular disease to cold with an estimated prevalence between 5-9 % of the general population. It is the expression of an extreme vasospasm microcirculation of the extremities linked to hypersensitivity to cold and that is clinically expressed by the occurrence of syncope stages where the fingers are anesthetized and white, followed by a stage with hyperemic restaining . The objective of our study is to identify new metabolic pathways involved in vasospasm in order to consider new specific treatments, currently lacking. The identification of these pathways will be made by the detection of genetic abnormalities causing vasospasm in Raynaud's phenomenon. This disease is a perfectly appropriate model to study vasospasm by its high frequency in the population, its hereditary nature and simple diagnosis. The powerful current genetic strategies will be applied to this model (exome sequencing combined to family connection analysis).
Detailed Description
Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases. In all participating centers, there will be a recruitment of index cases without family screening to form a series of cases that will validate the results obtained in family forms. The investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family. In all centers, relatives of included Index cases, agreeing to participate in this research, will be enrolled and followed. Nantes University Hospital is the only center to perform a cold test (for reasons of availability of the technique) but this test will be reserved for patients whose diagnosis of primary Raynaud's phenomenon would be doubtful. Exposed identified relatives, agreeing to participate in this research, will all be included and followed in their enrollment center.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Raynaud's Phenomenon (PR), Genetic Mutations Causing PR, Study of Patients and Their Relatives (With or Without Primary PR)
Keywords
Raynaud's phenomenon, Vasospasm, Genetics

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
258 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Patient with Raynaud's phenomenon
Arm Type
Experimental
Intervention Type
Genetic
Intervention Name(s)
Demonstration of genetic mutations causing Raynaud's phenomenon
Other Intervention Name(s)
Recruitment of familial forms of Raynaud phenomenon (patients with primary, Raynaud phenomenon and their relatives) to perform genetic analysis of, exome sequencing type combined with an analysis of family bonding.
Intervention Description
Such an approach allows to highlight chromosomal regions shared only by individuals within a family and thus highlight the genetic mutations causing the Raynaud phenomenon . The ultimate goal is to identify new pathways involved in vasospasm. Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases. The investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family.
Primary Outcome Measure Information:
Title
To identify number of genes involved in vasospasm of primary Raynaud's phenomenon (RP) and determine the genetic cause of primary RP
Description
Patients with primary Raynaud's phenomenon and their relatives will be recruited to establish familial forms of Raynaud's phenomenon. This will allow perform genetic analysis using new approaches to genetic broadband (exome sequencing analysis + linkage analysis). This approach will allow specify which chromosomal regions are shared only by affected individuals, and identify new candidate genes
Time Frame
36 months
Secondary Outcome Measure Information:
Title
To determine number of phenotypes associated to genotype of primary Raynaud's phenomenon
Description
Based on the identified genes in different families, a descriptive analysis will allow associate them with different RP phenotypes (isolated RP or RP associated with migraines, angina or hypertension) and risk factors.
Time Frame
36 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria: Major Subject (age ≥ 18 years) Index case with all the diagnostic criteria for primary Raynaud phenomenon, according to current recommendations OR Related index case (relatives' patients) with or without a primary Raynaud phenomenon. Written consent to participate in the study Written consent to participate in the collection of biological samples Exclusion criteria: Subjects who have expressed their inability or refusal to sign an informed consent, Index case with a secondary Raynaud phenomenon (suspected by clinical examination and confirmed by capillaroscopy and laboratory tests: antinuclear antibody, abnormalities of capillaroscopy mégacapillaire dystrophy or other major deviation). (Criterion not applicable to related parties, i.e. family members of Index cases) - Pregnant Woman.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marc-Antoine Pistorius, Prof
Organizational Affiliation
University Hospital of Nantes
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Marc-Antoine Pistorius, Prof
Organizational Affiliation
University Hospital of Nantes
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Luc Bressollette, Prof
Organizational Affiliation
University Hospital of Brest
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Patrick Jégo, Prof
Organizational Affiliation
University Hospital of Rennes
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Samir Henni, Dr
Organizational Affiliation
University Hospital of Angers
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jean-Manuel Kubina, Dr
Organizational Affiliation
Hospital of La Roche/Yon
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Pierre Plissonneau Duquene, Dr
Organizational Affiliation
Hospital of St Nazaire
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Angers - Service d'Explorations vasculaires
City
Angers
ZIP/Postal Code
49033 Angers Cedex 01
Country
France
Facility Name
CHRU HOPITAL CAVALE BLANCHE - Service de Médecine vasculaire
City
Brest
ZIP/Postal Code
29609 Brest Cedex 2
Country
France
Facility Name
CHD La Roche sur Yon - Service Angéiologie
City
La Roche sur Yon
ZIP/Postal Code
85925 La Roche/Yon Cedex 9
Country
France
Facility Name
CHU de NANTES - Service de Médecine Interne
City
Nantes
ZIP/Postal Code
44000
Country
France
Facility Name
C.H.R. HOPITAL SUD - Service de Médecine interne
City
Rennes
ZIP/Postal Code
35203 Rennes Cedex 2
Country
France
Facility Name
Ch Saint Nazaire
City
Saint Nazaire
ZIP/Postal Code
44600
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon

We'll reach out to this number within 24 hrs